NICE has recommended durvalumab for the maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation in final draft guidance, which reviewed the additional evidence collected as part of the Cancer Drugs Fund managed access agreement for the treatment.

Long-term evidence on the effectiveness of zanubrutinib is not yet available, and the cost-effectiveness estimate is higher than what is normally considered cost-effective, says NICE.

Venetoclax is accepted, in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy.

NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.

NICE has issued draft guidance which does not recommend the treatment based on limitations in the clinical evidence and cost-effectiveness uncertainties.